trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Carcinoma D002277 18 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Brain Neoplasms D001932 15 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Melanoma D008545 69 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Asthma D001249 52 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Intellectual Disability D008607 13 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Prostatic Hyperplasia D011470 20 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Myeloproliferative Disorders D009196 5 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Carcinoma, Renal Cell D002292 12 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Leukemia, Promyelocytic, Acute D015473 3 associated lipids
Stroke D020521 32 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Chen J and Kang JH Quercetin and trichostatin A cooperatively kill human leukemia cells. 2005 Pharmazie pmid:16320950
Wei M et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. 2005 Cancer Res. pmid:16322213
Marchion DC et al. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. 2005 Clin. Cancer Res. pmid:16322310
Hammond SM et al. Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. 2005 Leuk. Res. pmid:15541480
Chang S and Pikaard CS Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation. 2005 J. Biol. Chem. pmid:15516340
Yanada M et al. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. 2005 Oncol. Rep. pmid:16142337
Uchida H et al. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. 2005 Endocrinology pmid:16123169
Su M et al. Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells. 2005 J. Biol. Chem. pmid:16087680
Somech R et al. The nuclear-envelope protein and transcriptional repressor LAP2beta interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation. 2005 J. Cell. Sci. pmid:16129885
Cho HH et al. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. 2005 J. Cell. Biochem. pmid:16088945
Gurvich N et al. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. 2005 FASEB J. pmid:15901671
Peltonen K et al. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. 2005 Pigment Cell Res. pmid:15892716
Schwahn DJ et al. Dynamic regulation of the human dopachrome tautomerase promoter by MITF, ER-alpha and chromatin remodelers during proliferation and senescence of human melanocytes. 2005 Pigment Cell Res. pmid:15892717
Ranganathan P and Rangnekar VM Exploiting the TSA connections to overcome apoptosis-resistance. 2005 Cancer Biol. Ther. pmid:15908800
Rincón-Arano H et al. YY1 and GATA-1 interaction modulate the chicken 3'-side alpha-globin enhancer activity. 2005 J. Mol. Biol. pmid:15913647
Shetty S et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. 2005 Mol. Cell. Biol. pmid:15964798
Place RF et al. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. 2005 Biochem. Pharmacol. pmid:15950952
Wooten LG and Ogretmen B Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide. 2005 J. Biol. Chem. pmid:15951564
Xu S et al. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. 2005 J. Hum. Genet. pmid:15824892
Strait KA et al. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. 2005 Mol. Cancer Ther. pmid:15827334
Magner WJ and Tomasi TB Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. 2005 Mol. Immunol. pmid:15829293
Hu J and Colburn NH Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. 2005 Mol. Cancer Res. pmid:15755876
Senawong T et al. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. 2005 Arch. Biochem. Biophys. pmid:15639232
Zhao Y et al. Histone acetylation regulates both transcription initiation and elongation of hsp22 gene in Drosophila. 2005 Biochem. Biophys. Res. Commun. pmid:15607742
Kawano T et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. 2004 Sep-Oct Anticancer Res. pmid:15517875
Fenic I et al. In vivo effects of histone-deacetylase inhibitor trichostatin-A on murine spermatogenesis. 2004 Sep-Oct J. Androl. pmid:15292114
Emionite L et al. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. 2004 Nov-Dec Anticancer Res. pmid:15736447
Karasawa Y and Okisaka S Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells. 2004 Nov-Dec Jpn. J. Ophthalmol. pmid:15592778
Flørenes VA et al. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. 2004 Melanoma Res. pmid:15179185
Ahn MR et al. Trichostatin A, a histone deacetylase inhibitor stimulate CYP3A4 proximal promoter activity in Hepa-I cells. 2004 Arch. Pharm. Res. pmid:15180307
Vanhaecke T et al. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. 2004 Curr. Med. Chem. pmid:15180568
Kato N et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. 2004 Cell Death Differ. pmid:15153943
Ramakrishnan G et al. Histone acetyltransferases and deacetylase in Entamoeba histolytica. 2004 Mol. Biochem. Parasitol. pmid:15555732
Zoumpoulidou G et al. Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y). 2004 Mol. Endocrinol. pmid:15155784
Wang LG et al. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. 2004 Oncogene pmid:15156193
Romanski A et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. 2004 Haematologica pmid:15075075
Bayart E et al. A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. 2004 Cancer Res. pmid:15604258
Ishii S et al. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone. 2004 Mol. Endocrinol. pmid:15131262
Winn RA and Heasley LE Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. 2004 Chest pmid:15136458
Jin YH et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. 2004 J. Biol. Chem. pmid:15138260
Milutinovic S et al. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. 2004 J. Biol. Chem. pmid:15087453
Chang HC et al. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. 2004 Cell. Signal. pmid:15093608
Nishino N et al. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. 2004 Bioorg. Med. Chem. Lett. pmid:15109626
Marson CM et al. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. 2004 Bioorg. Med. Chem. Lett. pmid:15109636
Arapshian A et al. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. 2004 Mol. Cancer pmid:15113415
Mizukami T et al. Effects of trichostatin a, a histone deacetylase inhibitor, on mouse gonadal development in vitro. 2004 J. Reprod. Dev. pmid:15118250
Ganslmayer M et al. A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. 2004 Oncol. Rep. pmid:15069530
Margueron R et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. 2004 J. Mol. Endocrinol. pmid:15072561
Reifenberger J et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. 2004 Int. J. Cancer pmid:14961576
Sugimoto S et al. Expression and regulation of tumor suppressor gene maspin in human bladder cancer. 2004 Cancer Lett. pmid:14732229
Lu XC et al. [Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]. 2004 Zhongguo Shi Yan Xue Ye Xue Za Zhi pmid:14989767
Nojima H et al. Increase in DNA methylation downregulates conceptus interferon-tau gene expression. 2004 Mol. Reprod. Dev. pmid:14991730
Chua YL et al. Microarray analysis of chromatin-immunoprecipitated DNA identifies specific regions of tobacco genes associated with acetylated histones. 2004 Plant J. pmid:14996214
Khan AN et al. An epigenetically altered tumor cell vaccine. 2004 Cancer Immunol. Immunother. pmid:14997346
Ragno R et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. 2004 J. Med. Chem. pmid:14998325
Koch A et al. Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. 2004 Am. J. Respir. Cell Mol. Biol. pmid:12871851
Zelko IN and Folz RJ Sp1 and Sp3 transcription factors mediate trichostatin A-induced and basal expression of extracellular superoxide dismutase. 2004 Free Radic. Biol. Med. pmid:15451065
Chiba T et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. 2004 Oncology pmid:15452378
Jose B et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. 2004 Bioorg. Med. Chem. Lett. pmid:15454224
Uramoto H et al. p73 competes with co-activators and recruits histone deacetylase to NF-Y in the repression of PDGF beta-receptor. 2004 J. Cell. Sci. pmid:15454570
Wang S and Zhu J The hTERT gene is embedded in a nuclease-resistant chromatin domain. 2004 J. Biol. Chem. pmid:15516693
El-Khoury V et al. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells. 2004 Cytometry A pmid:15517561
Vaquero A et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. 2004 Mol. Cell pmid:15469825
Ladd PD et al. Identification of a genomic fragment that directs hematopoietic-specific expression of Rac2 and analysis of the DNA methylation profile of the gene locus. 2004 Gene pmid:15474314
Li H and Wu X Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. 2004 Biochem. Biophys. Res. Commun. pmid:15474507
Spenger A et al. Influence of promoter choice and trichostatin A treatment on expression of baculovirus delivered genes in mammalian cells. 2004 Protein Expr. Purif. pmid:15477077
Yee SB et al. Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion. 2004 Int. J. Oncol. pmid:15492835
Young JC et al. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. 2004 Cytotherapy pmid:16146885
Um SJ et al. In vitro antitumor potential of 4-BPRE, a butyryl aminophenyl ester of retinoic acid: role of the butyryl group. 2004 Oncol. Rep. pmid:14767528
Emmans VC et al. Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression. 2004 Biochem. Soc. Trans. pmid:15494029
Fan X et al. Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. 2004 J. Cell. Biochem. pmid:15389882
Astrand C et al. Trichostatin A reduces hormone-induced transcription of the MMTV promoter and has pleiotropic effects on its chromatin structure. 2004 Eur. J. Biochem. pmid:15009194
Chen YX et al. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. 2004 World J. Gastroenterol. pmid:15309711
Heltweg B et al. Subtype selective substrates for histone deacetylases. 2004 J. Med. Chem. pmid:15456267
Alikhani-Koopaei R et al. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. 2004 J. Clin. Invest. pmid:15489962
Marsili G et al. Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription. 2004 Ann. N. Y. Acad. Sci. pmid:15659847
Jang ER et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. 2004 Oncogene pmid:14676837
Thelen P et al. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. 2004 Int. J. Oncol. pmid:14654937
Kramps C et al. E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas. 2004 J. Biol. Chem. pmid:14645238
Chaturvedi V et al. Resistance to UV-induced apoptosis in human keratinocytes during accelerated senescence is associated with functional inactivation of p53. 2004 J. Cell. Physiol. pmid:14584049
Jansen MS et al. Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:15103026
Facchetti F et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. 2004 Apoptosis pmid:15314285
Roh MS et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. 2004 Apoptosis pmid:15314286
Yanaihara N et al. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. 2004 Int. J. Cancer pmid:15305387
Gaudier E et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15308471
Schultz BE et al. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. 2004 Biochemistry pmid:15323567
Tao D et al. Trichostatin A extends the lifespan of Drosophila melanogaster by elevating hsp22 expression. 2004 Acta Biochim. Biophys. Sin. (Shanghai) pmid:15346199
Korkmaz CG et al. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. 2004 J. Endocrinol. pmid:15350180
Akimoto T [Potentiation of radiation-induced cell killing by histone deacetylase inhibitor]. 2004 Nippon Rinsho pmid:15283155
Joung KE et al. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells. 2004 Arch. Pharm. Res. pmid:15283467
Kang J et al. Synergistic killing of human leukemia cells by antioxidants and trichostatin A. 2004 Cancer Chemother. Pharmacol. pmid:15248029
Jin B and Ryu DY Regulation of CYP1A2 by histone deacetylase inhibitors in mouse hepatocytes. 2004 J. Biochem. Mol. Toxicol. pmid:15252868
Gilchrist S et al. Nuclear organization of centromeric domains is not perturbed by inhibition of histone deacetylases. 2004 Chromosome Res. pmid:15254368
Li X et al. Regulation of histone acetylation and apoptosis by trichostatin in HL-60 cells. 2004 J. Huazhong Univ. Sci. Technol. Med. Sci. pmid:15791844
Lu H et al. Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. 2004 J. Virol. pmid:15194748
Moldenhauer A et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. 2004 J. Leukoc. Biol. pmid:15197237
Min KN et al. Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. 2004 Arch. Pharm. Res. pmid:15202563
Jia S et al. RNAi-independent heterochromatin nucleation by the stress-activated ATF/CREB family proteins. 2004 Science pmid:15218150
Sumer H et al. Effects of scaffold/matrix alteration on centromeric function and gene expression. 2004 J. Biol. Chem. pmid:15220334
Lee YJ et al. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein. 2004 Mol. Cells pmid:15179033